On this episode of Managed Care Cast, we speak with Tim Gronniger, the CEO of Caravan Health, about what to look for as accountable care organizations (ACOs) and policy makers try to encourage more providers to join value-based care arrangements.
The “muscles” that were created in value-based care programs in the years before the pandemic have been helpful to accountable care organizations (ACOs) in dealing with the turmoil in health care delivery, according to our guest on this week’s Managed Care Cast.
Tim Gronniger, MPP, MHSA, the CEO of Caravan Health, discusses what may come next (or ideally might come next) as ACOs move forward as the United States adjusts to an endemic phase of COVID-19. We discuss financing and policy and what is needed to achieve CMS’ goal of furthering the shift to ACOs by 2030.
Gronniger, former chief of staff and director of Delivery System Reform at CMS in the Obama administration, also discusses the company’s recent acquisition by Signify Health.
Listen above or through one of these podcast services:
Learning From Past Innovations to Advance Ventilation Use in Respiratory Conditions
May 21st 2024In a keynote presentation at ATS 2024, Hannah Wunsch, MD, MSc, of Weill Cornell Medicine, delved into how the history of breathing support dating back to the 1700s has set the stage for ventilation advances still being made today.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
ATS 2024 Data Support Triple Therapy FF/UMEC/VI as Preferred Option for COPD
May 21st 2024New data reveal that starting furoate/umeclidinium/vilanterol (FF/UMEC/VI) without delay not only significantly reduces exacerbations and health care costs but also enhances adherence and persistence for patients with chronic obstructive pulmonary disease (COPD) compared with other therapies.
Read More